After sifting through 10 years’ worth of clinical trial data, NCI’s Cancer Diagnosis Program says the program has identified about 100 “exceptional responders”: patients who responded well to drugs that the bulk of the trial population didn’t.

…read more

Source: National Cancer Institute investigating trial outliers to resurrect ‘failed’ drugs


0 No comments